ResMed, Verily Connect To Form Sleep Apnea JV
Sleep disorder therapy specialist ResMed and Alphabet's health unit Verily are combining their expertise to form a new joint venture focused on developing solutions that will enable health care providers to better diagnose and manage sleep apnea and other breathing-related sleep problems.
You may also be interested in...
Devices that collect and communicate patient data present opportunities for device-makers to have a closer relationship with end-users, but most device companies have little experience working directly with patients. Device firms need to close this gap by seeing the patients who use their devices as their primary customers, rather than just focusing on intermediaries like doctors, hospitals, and payers, industry experts tell Medtech Insight.
With half or more of all diagnosed obstructive sleep apnea patients who need continuous positive airway pressure machines unwilling or unable to use these devices, there’s a large unmet need for an alternative treatment. Startups are rising to the challenge with neuromodulation platforms, a mouthguard-like suction device, a nasal device with microblowers, and a vibrating device that nudges patients to turn on their sides.
In an interview with Medtech Insight following the J.P. Morgan Health Care Conference, Dexcom CEO Kevin Sayer discussed marketing plans for the next-generation G7 continuous glucose monitoring system and for the simpler CGM, Dexcom One, and outlined plans ahead.